ArticleArchives of dermatological research2025
Use of narrow-band ultraviolet B in pediatric dermatology patients: ten years of experience from a tertiary care hospital.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnology advances for psoriasis treatment and future prospects.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Narrow-band UVB (NB-UVB) phototherapy is a safe and effective treatment for pediatric skin disorders. We aimed to present the results of our 10-year experience of the efficacy and safety of NB-UVB phototherapy in children. We collected data from the phototherapy records of children aged < 17 years who received treatment between January 2013 and June 2023. The study included 108 patients, of whom 58 (53.7%) were female and 50 (46.3%) were male, with an average age of 12.6 years (range, 5-16 years). The most common skin diseases treated with NB-UVB phototherapy were psoriasis vulgaris (n = 40, 37.9%), vitiligo (n = 36, 33.3%), and guttate psoriasis (n = 12, 11.1%). The average duration of phototherapy for all patients was 5.88 months (ranging: 0.5-20.5 months), with a mean cumulative phototherapy dose of 29.0 J/cm
Indexed as
Identifiers
40126705What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.